TXG Stock Recent News

10x Genomics (TXG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024.

On track to deliver on full year production guidance for sixth consecutive year (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - July 9, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports Q2 2024 gold production of 113,822 ounces ("oz") and gold sold of 113,513 oz. With strong production of 229,316 oz through the first half of the year, the Company is on track to achieve annual gold production guidance of 400,000 to 450,000 oz.

Results indicate strong potential to further expand resources and continue to extend mine life (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces assay results from the Company's ongoing drilling program at El Limón Guajes ("ELG") Underground. The results to date support Torex's target of extending the mine life of ELG Underground beyond 2028 by identifying new zones of higher-grade mineralization, expanding resources, and increasing reserves.

Researchers used Chromium Single Cell products and Xenium In Situ to profile how gene expression is spatially regulated during secondary palate formation PLEASANTON, Calif., June 27, 2024 /PRNewswire/ -- 10x Genomics, Inc.  (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into cellular mechanisms regulating the formation of the secondary palate.

10x Genomics has experienced a significant decline in share price, currently trading around $20 per share, with no bullish indicators for a potential reversal. Recent performance shows growth in total revenue to $141M, but with a decrease in consumables revenue and a rise in operating costs, leading to an operating loss. Factors contributing to the decline in TXG include economic influences, fading growth prospects, supply chain issues, legal battles with NanoString Technologies, and a lack of retail investor interest.

New 5,000-plex gene panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , June 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel.

PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating 10x Genomics, Inc. (NASDAQ:TXG) on behalf of the company's stockholders. The investigation seeks to determine whether 10x Genomics and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors in connection with recent corporate actions.

Pipeline of high-quality targets systematically prioritized to unlock the full potential of Morelos (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - June 10, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide detail on a multi-year exploration strategy for its highly prospective Morelos Property ("Morelos"), designed to generate incremental additions to mineral resources in the near term, generate at least one new discovery in the mid-term, and extend the mine life at Morelos in order to deliver stable production and cash flow well beyond 2033. Jody Kuzenko, President & CEO of Torex, stated: "Since 2021, our exploration strategy has been focused on shoring up the near-term production profile and identifying future sources of feed to fill the mill beyond 2027.

New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , May 29, 2024 /PRNewswire/ --  10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel.